These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 32612616)

  • 1. Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.
    Miao Y; Fan L; Li JY
    Front Immunol; 2020; 11():1445. PubMed ID: 32612616
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies.
    Zhao M
    Int J Antimicrob Agents; 2020 Jun; 55(6):105982. PubMed ID: 32305588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The COVID-19 Cytokine Storm; What We Know So Far.
    Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
    Front Immunol; 2020; 11():1446. PubMed ID: 32612617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons from the Italian COVID-19 frontline.
    Bellan M; Sainaghi PP; Gavelli F; Patrucco F; Avanzi GC; Pirisi M; Castello LM
    Minerva Med; 2020 Aug; 111(4):303-305. PubMed ID: 33032392
    [No Abstract]   [Full Text] [Related]  

  • 5. COVID-19: Some clinical questions after the first 4 months.
    Bassetti M; Ansaldi F; Icardi G; Pelosi P; Robba C; Taramasso L; Trucchi C; Vena A; Giacobbe DR
    Eur J Clin Invest; 2020 Jul; 50(7):e13326. PubMed ID: 32562550
    [No Abstract]   [Full Text] [Related]  

  • 6. The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.
    Goker Bagca B; Biray Avci C
    Cytokine Growth Factor Rev; 2020 Aug; 54():51-62. PubMed ID: 32636055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-6: Relevance for immunopathology of SARS-CoV-2.
    Gubernatorova EO; Gorshkova EA; Polinova AI; Drutskaya MS
    Cytokine Growth Factor Rev; 2020 Jun; 53():13-24. PubMed ID: 32475759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focus shifts to antibody cocktails for COVID-19 cytokine storm.
    Harrison C
    Nat Biotechnol; 2020 Aug; 38(8):905-908. PubMed ID: 32760027
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytokine storm intervention in the early stages of COVID-19 pneumonia.
    Sun X; Wang T; Cai D; Hu Z; Chen J; Liao H; Zhi L; Wei H; Zhang Z; Qiu Y; Wang J; Wang A
    Cytokine Growth Factor Rev; 2020 Jun; 53():38-42. PubMed ID: 32360420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine release syndrome in severe COVID-19.
    Moore JB; June CH
    Science; 2020 May; 368(6490):473-474. PubMed ID: 32303591
    [No Abstract]   [Full Text] [Related]  

  • 11. Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.
    Chen LYC; Hoiland RL; Stukas S; Wellington CL; Sekhon MS
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32883678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
    Saha A; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Chakraborty C
    Arch Med Res; 2020 Aug; 51(6):595-597. PubMed ID: 32482373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
    Magro G
    Virus Res; 2020 Sep; 286():198070. PubMed ID: 32569708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?
    Liu B; Li M; Zhou Z; Guan X; Xiang Y
    J Autoimmun; 2020 Jul; 111():102452. PubMed ID: 32291137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.
    Takami A
    Int J Hematol; 2020 Jul; 112(1):122-124. PubMed ID: 32399895
    [No Abstract]   [Full Text] [Related]  

  • 17. Cytokines and COVID-19: friends or foes?
    Rokni M; Hamblin MR; Rezaei N
    Hum Vaccin Immunother; 2020 Oct; 16(10):2363-2365. PubMed ID: 32841579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.
    Hoiland RL; Stukas S; Cooper J; Thiara S; Chen LYC; Biggs CM; Hay K; Lee AYY; Shojania K; Abdulla A; Wellington CL; Sekhon MS
    Br J Haematol; 2020 Aug; 190(3):e150-e154. PubMed ID: 32584416
    [No Abstract]   [Full Text] [Related]  

  • 19. Potential strategies for combating COVID-19.
    Shamim S; Khan M; Kharaba ZJ; Ijaz M; Murtaza G
    Arch Virol; 2020 Nov; 165(11):2419-2438. PubMed ID: 32778950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons.
    Nile SH; Nile A; Qiu J; Li L; Jia X; Kai G
    Cytokine Growth Factor Rev; 2020 Jun; 53():66-70. PubMed ID: 32418715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.